## TN-1319

# Low-pg/mL Quantification of Cyclic Peptides in Rat plasma Using Microflow LC

Eshani Nandita, PhD<sup>1</sup>, Remco van Soest<sup>1</sup>, Zoe Zhang, PhD<sup>1</sup>, Elliot Jones<sup>1</sup>, and Bryan Tackett, PhD<sup>2</sup> <sup>1</sup>AB SCIEX LLC, 500 Old Connecticut Path, Framingham, MA 01701, USA <sup>2</sup>Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA

#### Introduction

This technical note describes the enhancement of lower limits of quantification (LLOQs) for cyclic peptides by using a microflow trap-and-elute method. Low-pg/mL quantification was achieved for human atrial natriuretic peptide (ANP) with outstanding reproducibility, precision, accuracy, and linearity. The microflow LC method achieved a 5-fold improvement in LLOQ, compared to previously published data acquired using analytical flow LC on a SCIEX® 7500 system. Cyclic peptides are polypeptides held in a ring configuration by chemically stable bonds, such as disulfide linkages. For example, the natriuretic peptide (NP) family is a group of genetically distinct cyclic peptides that contains an amino acid ring formed by disulfide bonds (**Figure 1**). The unique structure of these peptides can exhibit enhanced biological activity compared to traditional peptides. These features have helped identify cyclic peptides as important therapeutic candidates and successful therapeutic agents in cardiovascular diseases.

With emerging interest in the advancement of cyclic peptide therapeutics, there is an equivalent drive towards the development of highly robust and sensitive quantitative methods. Current bioanalytical methods lack the sensitivity necessary to reliably quantify cyclic peptides. For LC-MS based methods, high baseline interference in single MS mode and resistance to CID in MS/MS mode, given the tertiary structure, have an impact on overall sensitivity. In this study, human ANP was selected as a model analyte to evaluate improvement in sensitivity with the application of microflow LC. Low-level quantification was achieved for human ANP at an LLOQ of 0.01 ng/mL. The application of microflow LC yielded excellent accuracy, precision, and linearity, while providing outstanding quantitative performance in parallel with high sensitivity.

#### **Sample Preparation**

Rat plasma was protein precipitated and the supernatant was diluted 1:1 (v/v) with water which served as the processed biological matrix. Human ANP and a labeled cyclic peptide, internal standard (IS), were spiked into the processed rat plasma. The IS concentration was 10 ng/mL. Serial dilution with processed plasma was performed to create the calibration curves for analysis.

#### LC Conditions – Trap Column

Column:	Luna™ 5 µm C18(2)			
Dimensions:	20 x 0.3 mm			
Part No.:	<u>05M-4252-AC</u>			
Mobile Phase:	A: 0.1 % Formic A	cid in Water		
	B: 0.1 % Formic Acid in Acetonitrile			
Gradient:	Time (min)	%В		
	0	0		
	0.1	0		
	5	0		
	5.2	90		
	6.8	90		
	7	0		
	8.5	0		
Flow Rate:	50 μL/min			
Injection Volume:	20 µL			
Temperature:	Ambient			
LC System:	SCIEX M5 Microl	<u>.</u>		



#### LC Conditions – Analytical Column

Kinetex™ 2.6 µm XB-C18			
50 x 0.3 mm			
00B-4496-AC			
A: 0.1 % Formio	Acid in Water		
B: 0.1 % Formio	Acid in Acetonitrile		
Time (min)	%В		
0	40		
5	60		
5.2	90		
6.8	90		
7	40		
8.5	40		
5 μL/min			
20 µL			
40 °C			
SCIEX M5 MicroLC			
MRM			
SCIEX Triple Quad™ 7500			
	Kinetex <sup>™</sup> 2.6 μ $50 \times 0.3 \text{ mm}$ 00B-4496-AC A: 0.1 % Formid B: 0.1 % Formid Time (min) 0 5 5.2 6.8 7 8.5 5 μL/min 20 μL 40 °C SCIEX M5 Micro MRM SCIEX Triple Qu		

#### **MRM Conditions**

Polarity:	Positive
Source Temperature:	300 °C
GS1:	30
GS2:	80
CUR:	35
CAD:	11
IS:	4000 V

#### **MRM Parameters**

Compound	Q1 (m/z)	Q3 (m/z)	CE	СХР
Human ANP	617.1	584.1	34	15

#### **Results and Discussion**

In this workflow, a sensitive LC-MRM method was developed for the quantification of cyclic peptides in rat plasma. Human ANP was spiked into processed rat plasma at concentrations ranging from 0.01 ng/mL to 200 ng/mL. Calibration curves were measured in triplicates.

The LLOQ was determined based on the requirements that the %CV is below 20 % and accuracy is between 80 % and 120 %. For concentrations above the LLOQ, the %CV was required to be below 15 %, with accuracy between 85 % and 115 %. An LLOQ of 0.01 ng/mL was achieved, as shown in **Figure 2**. No significant matrix interferences were observed at the retention time of the analyte. The implementation of microflow LC resulted in a 5-fold improvement in sensitivity, compared to prior implementations of analytical flow LC on a SCIEX® 7500 system.

The linear range was between 0.01 ng/mL to 200 ng/mL for human ANP, providing 4.3 orders of magnitude in linear dynamic range (LDR) (Figure 3).

Calculated concentrations for all calibration points were within  $\pm 15$  % of the nominal value (**Table 1**). As shown in **Table 1**, the precision was less than 12.5 %, demonstrating high reproducibility. Overall, a highly sensitive method for the quantification of cyclic peptides was demonstrated. For human ANP, quantification at low-pg/mL levels was achieved.

#### Conclusions

An ultra-sensitive microflow LC-MRM based cyclic peptide quantification workflow using SCIEX 7500 system has been demonstrated in this work. Compared to previously published data acquired using analytical flow LC on a SCIEX 7500 system, a 5-fold improvement in LLOQ was achieved with the implementation of a microflow LC workflow. Low-level quantification was achieved for human ANP at an LLOQ of 0.01 ng/mL with exceptional reproducibility, accuracy, and linearity. The combination of the D Jet<sup>™</sup> ion guide, OptiFlow<sup>®</sup> Pro ion source, and E Lens<sup>™</sup> probe enabled a cumulative gain in sensitivity through improvement in ion generation, capture and transmission.

Figure 1. Amino Acid Sequence of Human ANP.



#### Figure 2. XICs of Matrix Blank and LLOQ of Human ANP.







#### Table 1. Concentration, Accuracy, and Precision for Human ANP.

Concentration (ng/mL)	Accuracy (%)	CV (%)
200	94.60	6.24
20	108.94	3.36
10	100.94	8.60
2	107.67	3.91
1	101.18	3.24
0.5	93.99	9.26
0.2	99.51	12.30
0.1	93.08	3.20
0.02	98.62	8.44
0.01	101.47	4.10

# TN-1317

### Luna<sup>™</sup> Ordering Information

3 μm and 5 μm Micro LC Columns (mm)							Trap Column	Trap Column	
Phases	50 x 0.30	100 x 0.30	150 x 0.30	50 x 0.50	100 x 0.50	150 x 0.50	250 x 0.50	20 x 0.30	20 x 0.50
3 μm C8(2)	00B-4248-AC	—	—	<u>00B-4248-AF</u>		—	—	—	
3 μm C18(2)	00B-4251-AC	00D-4251-AC	00F-4251-AC	00B-4251-AF	00D-4251-AF	00F-4251-AF		—	—
3 μm Phenyl-Hexyl		00D-4256-AC	—	—	00D-4256-AF				-
3 μm NH2		—	00F-4377-AC						_
3 μm HILIC		—	—	<u>00B-4449-AF</u>		—	—	—	—
5 μm C8(2)		—	00F-4249-AC	—				<u>05M-4249-AC</u>	<u>05M-4249-AF</u>
5 μm C18(2)		_	00F-4252-AC	_		00F-4252-AF	00G-4252-AF	05M-4252-AC	05M-4252-AF
5 μm Phenyl-Hexyl	00B-4257-AC	_	_	00B-4257-AF		_	_	_	_

# Kinetex<sup>™</sup> Ordering Information

2.6 μm Micro LC Columns (mm)							
Phases	30 x 0.3	50 x 0.3	100 x 0.3	150 x 0.3	50 x 0.5	150 x 0.5	
XB-C18	<u>00A-4496-AC</u>	00B-4496-AC	00D-4496-AC	00F-4496-AC	00B-4496-AF	00F-4496-AF	
Biphenyl	—	00B-4622-AC	—	00F-4622-AC	00B-4622-AF		
C18	<u>00A-4462-AC</u>	00B-4462-AC	—	00F-4462-AC	00B-4462-AF		
EVO C18		00B-4725-AC	—	00F-4725-AC	00B-4725-AF		
F5		00B-4723-AC	00D-4723-AC	00F-4723-AC	00B-4723-AF		



#### Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

India

Indonesia

Ireland

Japan t: +81 (0) 120-149-262

Mexico

t: +62 21 5019 9707

t: +353 (0)1 247 5405

Italy t: +39 051 6327511

Luxembourg t: +31 (0)30-2418700

t: 01-800-844-5226

The Netherlands

t: +31 (0)30-2418700

**New Zealand** 

**Norway** t: +47 810 02 005

t: +48 22 104 21 72

Poland

t: +64 (0)9-4780951

t: +91 (0)40-3012 2400

indiainfo@phenomenex.com

indoinfo@phenomenex.com

eireinfo@phenomenex.com

italiainfo@phenomenex.com

jpinfo@phenomenex.com

nlinfo@phenomenex.com

nlinfo@phenomenex.com

nzinfo@phenomenex.com

nordicinfo@phenomenex.com

pl-info@phenomenex.com

tecnicomx@phenomenex.com

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belaium t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

**Czech Republic** t: +420 272 017 077 cz-info@phenomenex.com

Denmark t: +45 4824 8048 nordicinfo@phenomenex.com

Finland t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

**Germany** t: +49 (0)6021-58830-0 anfrage@phenomenex.com

Hong Kong t: +852 6012 8162 hkinfo@phenomenex.com

#### www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right. www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/phx-terms-and-conditions-of-sale. Trademarks

Luna, Kinetex, and BE-HAPPY are trademarks of Phenomenex. SCIEX and OptiFlow are registered trademarks and Triple Quad, D Jet, and E Lens are trademarks of AB SCIEX Pte. Ltd.

Disclaimer Comparative separations may not be representative of all applications

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2022 Phenomenex, Inc. All rights reserved.

≥ FN49721022

Page 4 of 4



**Portugal** t: +351 221 450 488 ptinfo@phenomenex.com

Singapore t: +65 6559 4364 sginfo@phenomenex.com

Slovakia t: +420 272 017 077 sk-info@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

Sweden t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

Thailand t: +66 (0) 2 566 0287 thaiinfo@phenomenex.com

**United Kingdom** t: +44 (0)1625-501367 ukinfo@phenomenex.com

USA t: +1 (310) 212-0555 www.phenomenex.com/chat

All other countries/regions **Corporate Office USA** t: +1 (310) 212-0555 www.phenomenex.com/chat

Have questions or want more details on implementing this method? We would love to help! Visit www.phenomenex.com/Chat to get in touch with one of our Technical Specialists

